Primus In News
Tarnished by cough syrup deaths, India’s pharma industry tries to look beyond the stupor
21-07-2023
Nilaya Varma, Co-Founder and CEO of Primus Partners shares his views on the impact of the COVID-19 pandemic and the Russia-Ukraine war on vaccine exports from India, especially to African and Commonwealth of Independent States (CIS) countries. In addition, he stresses that the increasing cost of raw materials and the withdrawal of GST exemption has exacerbated challenges for Indian pharma companies. Read Now!
Explore Related Insights
- Leaderspeak: India Inc reacts to the Union Budget 2022
- RBI's newest pitch Unified Lending Interface: How will it revolutionise credit availability
- Hyderabad: Over 4,000 gaming enthusiasts attend India Game Developer Conference
- Rupee may lose further ground as RBI’s bond-buying plans dent sentiment: Analysts
